Minister for Enterprise Richard Bruton with American Chamber chief executive Mark Redmond and RIA executive director Laura Mahoney at the launch of the inaugural US-Ireland Research Innovation Awards

The inaugural US-Ireland Research Innovation Awards will be presented this Friday, May 15th, at the American Chamber of Commerce annual dinner in the (...)

Valeant Pharmaceuticals, the Canadian drugmaker known for its serial acquisitions, reported first-quarter profit that topped analysts’ estimates and r(...)

Some of the worst-performing funds in 2014 were ones managed by John Paulson, who rose to fame by making billions of dollars from a shrewd bet against the US housing market in the runup to the financial crisis.

If Steven A Cohen’s investment firm were operating as a hedge fund, it would have been one of the industry’s most profitable in 2014. Mr Cohen’s famil(...)

Botox is one of a number of pharmaceutical products made in Allergan’s Westport plant. Photograph: Shannon Stapleton/Files/Reuters

Allergan, the maker of Botox, has agreed to sell itself in a $66 billion (€53 billion) deal with fellow drugs group Actavis, with rival Valeant bowing(...)

Valeant had said it was willing to pay at least $200 a share and has the backing of Allergan’s largest shareholder -- activist investor Bill Ackman’s (pictured) Pershing Square Capital Management LP. ( Photograph: Scott Eells/Bloomberg)

Actavis has agreed to pay about $66 billion (€52.6bn) for Allergan, after the maker of Botox turned to the drugmaker to repel a hostile advance from V(...)

A doctor injects a patient with Allergan’s Botox. Photographer: Patrick T. Fallon/Bloomberg

Botox maker Allergan, which is fending off an acquisition by Valeant Pharmaceuticals, said today that it had been approached by another party regardi(...)

Botox producer Allergan  is resisting Valeant’s hostile offer. Photograph: Shannon Stapleton/Reuters

Valeant Pharmaceuticals said in a letter yesterday to Allergan’s board of directors that it was prepared to raise its offer to at least $200 per share(...)

 Allergan shareholder Paulson & Co is said to be urging the Botox maker to merge with specialty pharmaceutical company Shire. Photo: Eric Luke/The Irish Times

Allergan shareholder Paulson & Co is said to be urging the Botox maker to merge with specialty pharmaceutical company Shire as an alternative to (...)

The head offices of Valeant Pharmaceuticals International in Quebec. The ISS report comes as Allergan’s largest shareholder, hedge fund Pershing Square Capital Management, is urging the Botox maker to sell itself to Valeant. Photograph: Reuters/Christinne Muschi

Prominent investor shareholder advisory firm ISS called on Allergan to give its shareholders a chance to vote on any large, buyout-blocking acquisitio(...)

Pfizer has yet to formally put a value on the Actavis bid as it says no actual offer has been made, but it does make for a complicated chain all the same.

Keeping track of the merry-go-round that is pharma M&A is quite a challenge. It’s not all down to corporate inversion – that bête noir of US polit(...)